8-KOther EventsExhibits & Filings

Merck & Co., Inc. 8-K Report, Corporate Update (Jul 24, 2009)

Filed July 24, 2009For Securities:MRK

Summary

Merck & Co., Inc. (MRK) filed an 8-K on July 24, 2009, primarily to disclose details regarding a settlement of class action lawsuits related to its proposed merger with Schering-Plough Corporation. The settlement, agreed upon by Schering-Plough, aims to resolve claims that the Schering-Plough board breached fiduciary duties in connection with the merger announcement, particularly concerning the timing relative to the publication of Phase II trial results for Schering-Plough's drug TRA. While Merck is indirectly involved as the merger partner, the core of the litigation and settlement pertains to Schering-Plough's disclosures and board actions. The filing provides additional information on financial advisor fees, arbitration regarding specific drugs, and a timeline of public disclosures for the TRA-PCI trial. Investors should note that both companies deny the allegations in the consolidated complaint.

Key Highlights

  • 1Settlement reached in class action lawsuits challenging the proposed merger between Merck and Schering-Plough, initiated by Schering-Plough shareholders.
  • 2The litigation primarily alleges breach of fiduciary duties by Schering-Plough's board regarding the merger announcement timing relative to clinical trial results publication.
  • 3Additional disclosures provided regarding financial advisor fees for both Schering-Plough and Merck.
  • 4Information on arbitration concerning Remicade and golimumab is also disclosed, with references to prior filings.
  • 5Merck and Schering-Plough deny all allegations made in the consolidated amended complaint.
  • 6The filing includes tables showing stock prices for both companies during the week of the merger announcement and a timeline of public disclosures for the TRA-PCI trial.
  • 7Negotiations on the merger agreement included discussions and revisions to deal protection provisions, termination fees, and matching periods.

Frequently Asked Questions

The main purpose of this 8-K filing for Merck is to disclose a memorandum of understanding reached by Schering-Plough regarding the settlement of class action lawsuits challenging the proposed merger between the two companies. Merck is providing this information as part of the settlement terms agreed to by Schering-Plough.

The core allegations in the lawsuits claim that Schering-Plough's board of directors breached their fiduciary duties in connection with the proposed merger with Merck. Specifically, the plaintiffs allege issues with the timing of the merger announcement in relation to the publication of Phase II clinical trial results for Schering-Plough's drug TRA, which coincided with a notable increase in Merck's stock price.

While the settlement is primarily between Schering-Plough and the plaintiffs, Merck is indirectly involved as the merger partner. Schering-Plough has agreed to make additional disclosures and will pay attorneys' fees and expenses awarded by the court. There is no direct indication in this filing of immediate financial obligations for Merck related to the settlement itself, beyond the resources dedicated to the merger process.

No, this filing does not report any new significant business developments for Merck itself. Its primary focus is on providing updates related to the ongoing merger with Schering-Plough and addressing litigation surrounding that transaction.